Medicaid

2025-2026 Bill 5486: Medicaid - South Carolina Legislature Online

South Carolina General Assembly
126th Session, 2025-2026
Download
This Bill
in Microsoft Word Format
Indicates Matter Stricken
Indicates New Matter
H. 5486
STATUS INFORMATION
General Bill
Sponsors: Rep. Grant
Document Path: LC-0499VR26.docx
Introduced in the House on April 1, 2026
Currently residing in the House Committee on
Medical, Military, Public and Municipal Affairs
Summary: Medicaid
HISTORY OF LEGISLATIVE ACTIONS

Date

Body

Action Description with journal page number

4/1/2026

House

Introduced and read first time (
House Journal-page 8
)

4/1/2026

House

Referred to Committee on
Medical, Military, Public and Municipal Affairs
(
House Journal-page 8
)

View the latest
legislative information
at the website
VERSIONS OF THIS BILL
04/01/2026

A bill

TO AMEND THE SOUTH
CAROLINA CODE OF LAWS BY ADDING SECTION
44-6-120
SO AS TO REQUIRE THE
DEPARTMENT OF HEALTH AND HUMAN SERVICES TO CONDUCT AN ANNUAL REVIEW OF
MEDICATIONS AND TREATMENTS FOR CHRONIC AND RARE KIDNEY DISEASES FOR ENROLLEES
IN THE SOUTH CAROLINA MEDICAID PROGRAM IN ORDER TO DETERMINE THE ADEQUACY OF
THE AVAILABLE TREATMENTS AND TO MAKE RECOMMENDATIONS REGARDING POTENTIAL NEW
TREATMENTS; TO REQUIRE THE DEPARTMENT TO PUBLISH AN ANNUAL REPORT; AND FOR
OTHER PURPOSES.

B
e it enacted by the
General Assembly of the State of South Carolina:

S
ECTION 1.
A
rticle 1, Chapter 6, Title 44 of the S.C. Code is
amended by adding:

S
ection
44-6-120
.
(
A) The department shall
conduct an annual review of all medications and forms of treatment for chronic
and rare kidney diseases, and services for enrollees with a diagnosis of
chronic or rare kidney disease, that are eligible for coverage under the South
Carolina Medicaid program. The purpose of the annual review is to determine if
the available covered medications, treatments, and services are adequate to
meet the needs of enrollees with a diagnosis of chronic or rare kidney disease,
and whether the department should seek to add additional medications,
treatments, or services.

(
B)
When conducting the annual review required by this section, the department
shall solicit and consider input from the public, with specific emphasis on
attempting to receive input from persons or groups with knowledge and
experience in chronic and rare kidney diseases.

(
C) On
or before January 15, 2027, and on or before January fifteenth each year
thereafter, the department shall submit a report to the clerks of the Senate
and the House of Representatives for distribution to the appropriate subject
matter committees that details the findings from the annual review required by
this section, as well as any recommendations to the General Assembly based upon
those findings. The department shall publish the annual report required by this
subsection on its website in a manner accessible by the general public.

S
ECTION 2. This act takes effect upon approval
by the Governor.

----XX----

This web page was last updated on April 1, 2026 at 12:07 PM